Home > Resources > Whitepapers > BROADENING THE DEFINITION OF TOLERABILITY IN CANCER CLINICAL TRIALS TO BETTER MEASURE THE PATIENT EXPERIENCE

BROADENING THE DEFINITION OF TOLERABILITY IN CANCER CLINICAL TRIALS TO BETTER MEASURE THE PATIENT EXPERIENCE

November 7, 2018

Robust safety and tolerability data are essential in cancer therapeutic studies, and some trials are specifically designed with a key objective of demonstrating improved safety and tolerability. The development of a clinical trial framework and data elements to demonstrate comparative safety and tolerability requires a suite of endpoints and approaches to enable meaningful interpretation of results for regulatory and clinical decision-making.

Spotlight

Cardiovent

Cardiovent is one of the most specialized companies in the market for solutions for the hospital environment. Representative of the leading medical systems brands Maquet, ArjoHuntleigh and Getinge, in Rio de Janeiro and Espírito Santo, Cardiovent brings together hospitals and homecare cases with innovative products and services.

OTHER WHITEPAPERS

Shifting to an Audience-Focused Product Marketing Strategy

whitePaper | February 24, 2023

The WBR Insights research team surveyed 100 leaders from pharmaceutical companies to generate the results featured in this report. The respondents occupy roles in marketing, sales, commercial strategy, and product development.

Nanoform Management Presentation

whitePaper | May 24, 2022

Our proprietary nanoforming technologies and services span the full range of drug development from small-molecule nanoparticles to large-molecule biologics.

Navigating the Drug Development Pipeline: Expertise for Highly Potent API Product Handling

whitePaper | July 11, 2022

The expansion in the development and manufacturing of highly potent active pharmaceutical ingredients (HPAPIs) and complex active pharmaceutical ingredients (APIs) has grown tremendously as demands in healthcare to bring newer therapies to market quicker increase.

Ultimate Pharma Messaging Guidebook

whitePaper | March 10, 2023

This pharma messaging guidebook features 20 proven cognitive science techniques that can be used to optimize pharmaceutical claims and messages.

Regenerative Medicine

whitePaper | September 16, 2022

T wice a year, we survey the cell and gene therapy landscape and ARM’s initiatives to advance the sector and provide an update to our members.

The Globalization Of The Pharmaceutical Industry

whitePaper | July 7, 2023

Rapid globalization has brought both opportunity and challenges for the pharmaceutical industry. Established healthcare markets are placing increased demands on industry to ensure products are beneficial, safe and available for patients and to improve how information is shared.

BROADENING THE DEFINITION OF TOLERABILITY IN CANCER CLINICAL TRIALS TO BETTER MEASURE THE PATIENT EXPERIENCE